Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02125461) enrolled 713 people in total — 476 received durvalumab (also known as MEDI4736) and 237 received a placebo (an inactive treatment used for comparison). The trial was measuring two main things: how long participants went without their disease getting worse (called progression-free survival), and how long participants lived overall (called overall survival). Several secondary measures were also tracked, including how many participants' tumours shrank, how long those responses lasted, and what proportion of participants were still alive and progression-free at 12 and 18 months after joining the trial. The reported data shows that, for progression-free survival, the median time without disease worsening was 16.8 months in the durvalumab group compared with 5.6 months in the placebo group. (Median means the point at which half the participants had experienced that outcome and half had not.) For overall survival, the median had not yet been reached in the durvalumab group at the time of reporting — meaning enough participants in that group had not yet died for a midpoint to be calculated — while the placebo group's median overall survival was reported as 28.7 months. Regarding tumour shrinkage (objective response rate), 30.0% of the durvalumab group and 17.8% of the placebo group were reported to have had their tumours shrink by a meaningful amount. For how long those responses lasted, the median duration had not been reached in the durvalumab group, while it was 18.4 months in the placebo group. At 12 months, 55.9% of the durvalumab group and 35.3% of the placebo group were reported to be alive and progression-free; at 18 months, those figures were 44.2% and 27.0% respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lung Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must be at least 18 years old
- You must have been diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that is at an advanced stage (Stage III) and cannot be removed by surgery
- You must have already received at least 2 cycles of a chemotherapy treatment containing platinum, given at the same time as radiation therapy
- You must be in generally good health and able to carry out daily activities with little or no difficulty (confirm with trial site)
- Your doctor must estimate that you are expected to live for more than 12 weeks
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously been treated with certain types of immunotherapy drugs known as anti-PD-1 or anti-PD-L1 antibodies
- You have, or have had in the past, a condition where your immune system attacks your own body, or a condition that weakens your immune system
- You have serious or uncontrolled health conditions, including active bleeding problems, or active infections such as Hepatitis B, Hepatitis C, or HIV
- You have uncontrolled conditions such as heart failure with symptoms, very high blood pressure that cannot be managed, or chest pain caused by reduced blood flow to the heart
- You are still experiencing side effects from your previous chemotherapy and radiation treatment that are more than mild in severity (confirm with trial site)
- You have, or have had in the past, an inflammatory bowel disease such as Crohn's disease or ulcerative colitis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 13 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Overall Survival
Other options
Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.